Pulmonx Corp is a high-risk healthcare company in the United States that specializes in providing minimally invasive treatments for severe emphysema patients. Their solutions, including the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the StratX Lung Analysis Platform, are popular in key markets such as the United States, Europe, Middle-East, Africa, Asia Pacific, and beyond. With a Risk Rating Score of 31.2, Pulmonx Corp focuses on ESG principles to drive sustainability and governace in their operations.